Jacqueline Zummo Sells 21,224 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 21,224 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the transaction, the insider now directly owns 98,861 shares of the company’s stock, valued at approximately $447,840.33. This represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Protara Therapeutics Stock Performance

Shares of TARA opened at $4.58 on Friday. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The business has a 50-day moving average of $4.27 and a 200 day moving average of $3.67. The firm has a market cap of $168.39 million, a P/E ratio of -1.62 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. As a group, research analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TARA has been the topic of several research analyst reports. Cantor Fitzgerald initiated coverage on Protara Therapeutics in a research report on Friday, March 14th. They issued an “overweight” rating on the stock. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price target for the company. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. Finally, HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Thursday, March 6th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $22.50.

Institutional Investors Weigh In On Protara Therapeutics

Several institutional investors have recently made changes to their positions in TARA. Toronto Dominion Bank bought a new stake in shares of Protara Therapeutics during the 4th quarter valued at $11,030,000. Velan Capital Investment Management LP grew its holdings in Protara Therapeutics by 175.1% during the 4th quarter. Velan Capital Investment Management LP now owns 1,579,000 shares of the company’s stock valued at $8,337,000 after buying an additional 1,005,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics during the fourth quarter valued at about $110,000. Millennium Management LLC lifted its holdings in shares of Protara Therapeutics by 2,479.2% in the fourth quarter. Millennium Management LLC now owns 371,453 shares of the company’s stock worth $1,961,000 after buying an additional 357,051 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new position in shares of Protara Therapeutics in the fourth quarter valued at approximately $7,392,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.